| Literature DB >> 32927786 |
Alessia Gallo1, Matteo Bulati1, Vitale Miceli1, Nicola Amodio2, Pier Giulio Conaldi1,3.
Abstract
The awareness of viruses as a constant threat for human public health is a matter of fact and in this resides the need of understanding the mechanisms they use to trick the host. Viral non-coding RNAs are gaining much value and interest for the potential impact played in host gene regulation, acting as fine tuners of host cellular defense mechanisms. The implicit importance of v-ncRNAs resides first in the limited genomes size of viruses carrying only strictly necessary genomic sequences. The other crucial and appealing characteristic of v-ncRNAs is the non-immunogenicity, making them the perfect expedient to be used in the never-ending virus-host war. In this review, we wish to examine how DNA and RNA viruses have evolved a common strategy and which the crucial host pathways are targeted through v-ncRNAs in order to grant and facilitate their life cycle.Entities:
Keywords: immune evasion; miRNA mimicry; viral circRNA; viral non-coding RNA
Year: 2020 PMID: 32927786 PMCID: PMC7549346 DOI: 10.3390/ncrna6030038
Source DB: PubMed Journal: Noncoding RNA ISSN: 2311-553X
Currently known immune mechanisms and target genes influenced by v-ncRNAs.
| Mechanisms Influenced | Target Genes | Molecular Mechanism | v-ncRNAs | References |
|---|---|---|---|---|
| PKR, Dicer | PKR and Dicer binding and competitive inhibition | EBERs (EBV) | [ | |
| IRF4 | Downregulation of IRF4-responsive promoter | PAN-RNA (KSHV) | [ | |
|
| STAT2 | STAT2 binding and depletion via proteasomal degradation | sfRNA1, sfRNA2 (Zika) | [ |
| ISGs | viral RNA-binding ISGs binding and competitive inhibition | sfRNAs (JCV, WNV, Dengue) | [ | |
| RIG-1 | 3′ UTR RIG-I mRNA binding and inhibition of protein expression | ebv-miR-BART6-3p (EBV) | [ | |
| CREBBP | 3′ UTR CREBBP mRNA binding and degradation induction | ebv-miR-BART16 (EBV) | [ | |
| IKKε | 3′ UTR IKKε mRNA binding and inhibition of protein expression | kshv-miR-K12-11 (KSHV) | [ | |
| IL-6R | mRNA binding and degradation induction | ebv-miR-BART6-3p (EBV) | [ | |
| TWEAKR | 3′ UTR TWEAKR mRNA binding and degradation induction | kshv-miR-K12-10 (KSHV) | [ | |
|
| IL-1R | mRNA binding and and degradation induction | ebv-miR-BHRF-1-2-5p (EBV) | [ |
| IL-1β pathway | 3′ UTR NLRP3 mRNA binding | ebv-miR-BART15 (EBV) | [ | |
| MyD88 | 3′ UTR MyD88 mRNA binding and inhibition of protein expression | kshv-miR-K12-5 (KSHV) | [ | |
| IRAK1 | 3′ UTR IRAK1 mRNA binding and inhibition of protein expression | kshv-miR-K12-9 (KSHV) | [ | |
| CTSB (MHC-1) | 3′ UTR CTSB mRNA binding and degradation induction | ebv-miR-BART2m (EBV) | [ | |
| TAP2 (MHC-1) | 3′ UTR TAP2 mRNA binding and inhibition of protein expression | ebv-miR-BHRF1-3 (EBV) | [ | |
|
| LY75 (MHC-1) | 3′ UTR LY75 mRNA binding and inhibition of protein expression | ebv-miR-BART1-5p (EBV) | [ |
| IFI30 (MHC-II) | 3′ UTR IFI30 mRNA binding and degradation induction | ebv-miR-BART1 (EBV) | [ | |
| LGMN (MHC-II) | 3′ UTR LGMN mRNA binding and degradation induction | ebv-miR-BART2 (EBV) | [ | |
|
| SP100 (CXCL8) | 3′ UTR SP100 mRNA binding and translational repression | MCV-miR-M1-5p (MCPyV) | [ |
| BCL11A, CHD7, ITGAM, RAG-1, TCEA1 | In silico analysis | HPV16-miR-H1-1 (HPV) | [ | |
| SP3, XRCC4, JAK2, PKNOX1, FOXP1 | In silico analysis | HPV16-miR-H2 (HPV) | [ | |
| IL12B | 3′ UTR IL12B mRNA binding and degradation induction | ebv-miR-BART1, -miR-BART2, -miR-BART10, | [ | |
|
| CXCL11 | CXCL11 mRNA binding and inhibition of protein expression | ebv-miR-BHRF1-3 (EBV) | [ |
| Viral T Antigen | ncRNA sequence binding | sv40-miR-S1, jcv-miR-J1 (JCV, BKV, | [ | |
| ASP | Noncoding promoter silencing | HIV-ncRNAs | [ | |
| Importin-α5 | 3′ UTR Importin-α5 mRNA binding and inhibition of protein expression | EBOV-miR-1-5p (Ebola) | [ | |
|
| MICB | 3′ UTR MICB mRNA binding and inhibition of protein expression | cmv-miR-UL112-1 (CMV), ebv-miR-BART2-5p (EBV), kshv-miR-K12-7 (KSHV) | [ |
| ULBP3 | 3′ UTR ULBP3 mRNA binding and protein translation inhibition | Jcv-miR-J1-3p (JCV, BKV) | [ |
Figure 1Viral mechanisms for host immune surveillance evasion by production of v-ncRNAs. The production of v-ncRNAs acts on the main mechanisms by which host immune effector cells oppose virus infection. This leads to escape from immune recognition with consequent virus proliferation/propagation.
Figure 2Role of v-ncRNAs in the virus pathogenesis mechanisms. V-ncRNAs act as fine regulators between the latent and lytic phase and as regulators of both survival and cell transformation. The control of these host physiological processes contribute to virus replication/propagation and cell pathogenesis.
Pathogenetic mechanisms influenced by v-ncRNAs.
| Mechanisms Influenced by v-ncRNAs | Target Genes | v-ncRNAs | Reference |
|---|---|---|---|
| TIA-1 | mivaRNAI-138 (Adenovirus) | [ | |
| PKR/eIF-2 | VAI-RNA (Adenovirus) | [ | |
| TGFβ1, SMAD3 | LAT (HSV-1) | [ | |
| ActD | miR-H3, miR-H4-3p, miR-H4-5p, miR-H24, miR-H19 (HSV-2) | [ | |
|
| CASP3, PUMA, p53 | EBV-miRNAs | [ |
| CASP3 | kshv-miR-K12-1, -miR-K12-3, -miR-K12-4-3p (KSHV) | [ | |
| p21 | kshv-miR-K12-1 (KSHV) | [ | |
| Mithocondrial Complex -1 | β-2.7 (MCPyV) | [ | |
| CASP7 | sfRNAs (Zika) | [ | |
| BclAF1 | cmv-miR-UL112-1 (CMV), ebv-miR-BART-17-5p (EBV), kshv-miR-K5 (KSHV) | [ | |
| EZH2, DNMT3a, HDAC1 | HIV1-ncRNAs | [ | |
| HSV1-sisRNAs | [ | ||
| CMV-sisRNAs | [ | ||
| EBV-sisRNA-1 | [ | ||
| JMJD3, UTX, LANA | PAN-RNA (KSHV) | [ | |
| MAPK | cmv-miR-UL70 (CMV) | [ | |
|
| IE72 | cmv-miR-UL112 (CMV) | [ |
| MAPK, TSPYL2, FXYD2, TAOK2, ST7L, TP73 | cmv-miR-UL112 (CMV) | [ | |
| RNF38, NKIRAS2 | ebv-miR-BART8-3p, -miR-BART13 (EBV) | [ | |
| MAP3K2 | ebv-miR-BART18-5p (EBV) | [ | |
| IkB, NFkB | kshv-miR-K1, -miR-K12-1 (KSHV) | [ | |
| Rbl2 | kshv-miR-K12-4-5p (KSHV) | [ | |
| PAN-RNA (KSHV) | [ | ||
| eIF-2 kinase | EBER1, EBER2 (EBV) | [ | |
|
| FOXP1 | ebv-miR-BART11 (EBV) | [ |
| PTEN | ebv-miR-BART7-3p (EBV) | [ | |
| RNF38 | ebv-miR-BART8-3p (EBV) | [ | |
| CASTOR1 | KSHV-miRNAs | [ |